World AstraZeneca woes grow as Australia, Philippines, African Union curb COVID shots
Canada pauses AstraZeneca vaccine for under 55
TORONTO (AP) — Canada on Monday suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 following concerns it might be linked to rare blood clots. The National Advisory Committee on Immunization had recommended the pause for safety reasons and the Canadian provinces, which administer health in the country, announced the suspension Monday. “There is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks,” said Dr. Shelley Deeks, vice chair of the National Advisory Committee on Immunization.
(Reuters) - Australia and the Philippines limited use of AstraZeneca's COVID-19 vaccine on Thursday, while the Africa Union dropped plans to buy the shot, dealing further blows to the company's hopes to deliver a vaccine for the world.
The vaccine - developed with Oxford University and considered a frontrunner in the global vaccine race - has been plagued by safety concerns and supply problems since Phase III trial results were published in December, with Indonesia the latest country forced to seek doses from other vaccine developers.
UK finds 30 blood clot cases after AstraZeneca jab
The cases identified by the medicines regulator were out of more than 18 million doses given.The Medicines and Healthcare products Regulatory Agency (MHRA) says the risk of having this type of clot is "very small".
The Philippines suspended the use of AstraZeneca shots for people below 60 after Europe's regulator said on Wednesday it found rare cases of blood clots among some adult recipients although the vaccine’s advantages still outweighed its risks.
Australia recommended people under 50 should get Pfizer's COVID-19 vaccine in preference to AstraZeneca's, a policy shift that it warned would hold up its inoculation campaign.
The African Union is exploring options with Johnson & Johnson having dropped plans to buy AstraZeneca's vaccine from India's Serum Institute, the head of the Africa Centres for Disease Control and Prevention told reporters.
AstraZeneca's shot is sold at cost, for a few dollars a dose. It is by far the cheapest and most high-volume launched so far, and has none of the extreme refrigeration requirements of some other COVID-19 vaccines, making it likely to be the mainstay of many vaccination programmes in the developing world.
NFL eyeing onsite offseason workouts; NFLPA prefers virtual setup
The NFL indicated meetings will likely remain virtual for the foreseeable future, but this year’s offseason workouts are not expected to be fully virtual like they were in 2020. However, the union has offered pushback to an onsite offseason returning this year.As of now, teams can schedule onsite OTAs to begin April 19. This is, however, contingent on no offseason plan being agreed to between the NFL and NFLPA. The union has offered pushback to an onsite offseason returning this year, with Mike Florio of Pro Football Talk reporting little progress has been made between the sides on this front.
But more than a dozen countries have at one time suspended or partially suspended use of the shot, first on concerns about efficacy in older people, and now on worries about rare side effects in younger people.
That, coupled with production setbacks, will delay the rollout of vaccines across the globe as governments scramble to find alternatives to tame the pandemic which has killed more than 3 million.
Italy joined France, the Netherlands, Germany and others in recommending a minimum age for recipients of AstraZeneca's shot on Wednesday and Britain said people under 30 should get an alternative. South Korea also suspended use of the vaccine in people under 60 this week, while approving Johnson & Johnson's shot.
AstraZeneca has said it is working with the British and European regulators to list possible brain blood clots as "an extremely rare potential side-effect".
How AstraZeneca's vaccine got mired in politics and mistrust to become Europe's least favorite shot
A succession of communication blunders about the vaccine has led some Europeans to see it as second rate.Merkel's interview with the Frankfurter Allgemeine Zeitung came as governments across Europe realized that mistrust among its people for this particular shot imperiled the continent's entire vaccination drive.
South Africa also paused AstraZeneca vaccinations last month because of a small trial showing the shot offered minimal protection against mild to moderate illness caused by the dominant local coronavirus variant.
AstraZeneca is grappling with production issues that have led to shortfalls of its shot in several countries.
Indonesian Health Minister Budi Gunadi Sadikin said on Thursday the country was in talks with China on getting as many as 100 million COVID-19 vaccine doses to plug a gap in deliveries after delays in the arrivals of AstraZeneca shots.
India has put a temporary hold on all major exports of AstraZeneca's shot made by the Serum Institute of India (SII), the world’s biggest vaccine-maker, as domestic infections rise.
That has affected supplies to the GAVI/WHO-backed global COVAX vaccine-sharing facility through which 64 poorer countries are supposed to get doses from the SII, the programme’s procurement and distributing partner UNICEF told Reuters last month.
Britain is slowing its vaccine rollout due to a shipment delay from India and is at loggerheads with the EU over exports. Australia has also blamed delays in its immunisation campaign on supply issues in Europe.
AstraZeneca has cited reduced yields at a European factory behind the supply shortfall to the European Union.
(Reporting by Reuters bureaux worldwide; Writing by Kirsten Donovan; Editing by Nick Macfie)
Australia to buy extra 20 million doses of Pfizer vaccine .
CANBERRA, Australia (AP) — Australia said Friday that it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine. Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50. He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year, enough to inoculate 20 million people in the nation of 26 million.